Dose-ranging and safety with intravenous levosimendan in low-output heart failure: experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial
- 24 June 1999
- journal article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 83 (12) , 21-25
- https://doi.org/10.1016/s0002-9149(99)00314-8
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass graftingPublished by Oxford University Press (OUP) ,1998
- Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captoprilEuropean Journal of Clinical Pharmacology, 1996
- Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiencyBasic Research in Cardiology, 1996
- Safety of Levosimendan and Other Calcium SensitizersJournal of Cardiovascular Pharmacology, 1995
- Dose-Range Study of a New Calcium Sensitizer, Levosimendan, in Patients with Left Ventricular DysfunctionJournal of Cardiovascular Pharmacology, 1995
- Acute effects of dobutamine on myocardial oxygen consumption and cardiac efficiency measured using carbon-11 acetate kinetics in patients with dilated cardiomyopathyJournal of the American College of Cardiology, 1993